Published • loading... • Updated
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
The regimen cut the risk of death and extended progression-free survival, with nearly 40% of patients alive at 3 years, BeOne said.
Summary by mykxlg.com
4 Articles
4 Articles
New data from the HERIZON-GEA-01 Phase 3 study demonstrate a total survival after 36 months of nearly 40% with the use of TEVIMBRA in combination with ZIIHERA and chemotherapy, with the median total survival (OS) reaching 27 months. For the treatment arm with TEVIMBRA, a median total survival was observed that was four months longer than in […]
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
